SEED Innovations Ltd (AIM:SEED) reported results for the six months to 30 September where it realised a £1.9mln gain from the sale of its stake in EMMAC Life Sciences, a 1.86 times return on the original investment, and made two investments into new companies.
However, while positive progress was reported for all its investee companies, the SEED board has been frustrated by recent unfavourable stock market sentiment around cannabis-related companies.
Publicly listed cannabis stocks across the globe have come under pressure in the past six months, leading to SEED’s net asset value at 30 September 2021 of £23.35mln being down from £24.94mln at the end of March. Net assets per share were 10.98p compared to 11.72p six months earlier.
Chairman Ian Burns said the company remains a firm believer in investing in the medical cannabis, health and wellness space, and is well positioned to capitalise on growth in the short, medium and long term.
The two new investments in the half-year were a €3mln invested in Germany’s Eurox Group, a revenue generating, vertically integrated medical cannabis company, and £175,000 in research-led cannabis healthcare company CiiTECH Limited ahead of an agreed London listing.
Burns said SEED is evaluating a large number of potential investment opportunities brought in by its strengthened investment analysis team.
He concluded: “As one of the only London-listed vehicles that provides exposure to opportunities in the health, wellness and medical cannabis spaces, and with a strong balance sheet, I am confident of SEED's continually evolving future and look forward to reporting on further progress over the coming months.”